Lumida
/CYTK
⌘K
Cytokinetics Inc

Cytokinetics Inc

CYTK
$73.77USD↑+0.20%+0.15 today

MARKET CAP

10.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$74 – $76

52W RANGE

$47
$88

AI Summary

Stalk
StalkMedium

CYTK remains under distribution pressure, with price rejecting at the 9- and 20-period EMAs and approaching its rising 200-day SMA. The active Post-Parabola Collapse pattern identifies mean-reversion eligibility, shifting the medium-term bias to bullish despite the short-term downtrend. However, tactical execution remains unfavorable until price can reclaim and accept above the short-term EMAs. Therefore, entries should be deferred ("Stalk") around the 200-day SMA support, awaiting a clear reversal signal.

  • ↑Q2'26 myCORSO revenues reached $25.3M with >700 prescribers onboard.
  • ↑Achieved ~90% Medicare parity and >50% commercial coverage for myCORSO.
  • ↓Q2'26 net loss widened to $198.8M ($1.50/share) from $134.4M.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Cytokinetics, Inc. (NASDAQ: CYTK) is a biopharmaceutical company specializing in innovative therapies addressing serious muscular diseases, particularly in cardiovascular conditions like hypertrophic cardiomyopathy (HCM). The company has gained momentum with the commercial launch of myCORSO, its lead product, targeting obstructive HCM and preparing for expansions into non-obstructive HCM. This places Cytokinetics at the forefront of the evolving cardiology landscape, with a focus on unique therapies to meet critical unmet patient needs.

Bull says

  • ↑Q2'26 myCORSO revenues reached $25.3M with >700 prescribers onboard.
  • ↑Achieved ~90% Medicare parity and >50% commercial coverage for myCORSO.
  • ↑Supplemental NDA for afikampton in non-obstructive HCM planned Q4'26.
  • ↑Upcoming ACACIA-HCM Phase 3 data could validate afikampton efficacy.
  • ↑Cash balance of $1.7B at end Q2'26 supports R&D and launch.
  • ↑Strong momentum and liquidity factors indicate favorable trading conditions.

Bear says

  • ↓Q2'26 net loss widened to $198.8M ($1.50/share) from $134.4M.
  • ↓Q2'26 revenue fell to $28.6M from $66.8M YoY, driven by milestone timing.
  • ↓Negative earnings yield and weak profitability factors signal valuation risk.
  • ↓FDA approval timeline for afikampton remains uncertain, potential delays.
  • ↓Prescription fulfillment bottlenecks could delay revenue realization.
  • ↓Interest-rate sensitivity and high operational expenses may strain cash burn.

Investment themes with CYTK

Biotech↓ -1.57%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q4 2023 · Mgmt. Guidance

Updated 04-15-2025neutral

Transcript signals

Bull points

  • And we anticipate that will mediate confer lifelong benefit for patients in terms of symptomatic and functional improvement and we could also hypothesize reduced risk of cardiovascular events.
  • During the quarter, we shared top line results from SEQUOIA-HCM, which as Robert said, exceeded our expectations. It was a truly extraordinary milestone reflective of an incredible commitment from so many, including our investigators, study staff, patients and of course, our teams at Cytokinetics. The results of SEQUOIA-HCM showed that treatment with aficamten significantly improved exercise capacity compared to placebo, increasing peak oxygen uptake or peak VO2, measured by cardiopulmonary exercise testing, by a least square mean difference of 1.74 milliliters per kilogram per minute with a p-value of 0.000002.
  • The treatment effect with aficamten was consistent across all pre-specified subgroups, reflective of patient baseline characteristics and treatment strategies, including patients receiving or not receiving background beta blocker therapy.

Bear points

  • we announced the retirement of Ching Jaw from his position as CFO in order to attend to his personal health, and Ching's departure is unrelated to our business prospects, but it represents a potential concern for operational continuity.
  • despite projecting an increase in our expected operating expenses in 2024
  • $420 million to $450 million
Read full transcript analysis ›